DBS-based Biomarkers of Neurodegeneration predict Cognitive Decline and Dementia Seven Years Ahead in a Large Population-Based Sample
Boersch-Supan, A.; Borbye-Lorenzen, N.; Deza-Lougovski, Y.; Douhou, S.; Kneip, T.; Otero, M. C.; Pettinicchi, Y.; Boersch-Supan, M.
Show abstract
INTRODUCTIONIt is unknown whether biomarkers of neurodegeneration collected from dried blood spots (DBS) in large-scale population settings are useful in predicting cognitive decline many years later. METHODSIn 2015, we collected DBS of 13,679 individuals aged 58 and older. All DBS were assayed for ApoE4 protein, and a smaller subsample for pTau217, GFAP, and NfL. In 2022, we obtained detailed cognition measures for 6,523 respondents. Regression analyses tested the likelihood of cognitive impairment as a function of biomarker levels. RESULTSRespondents with ApoE4 detection have worse cognitive performance seven years later as measured by six different cognitive performance measures (p<0.001). The combination of all four biomarkers is a statistically significant predictor for five cognitive performance measures, with pTau217 having the most systematic association. DISCUSSIONDBS-based biomarkers of neurodegeneration provide a cost-efficient and scalable early warning signal enabling preventive measures against AD/ADRD before the onset of serious symptoms.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- DNA methylation age acceleration is associated with incident cognitive impairment in the Health and Retirement Study 95%
- Race/Ethnic Disparities in Mild Cognitive Impairment and Dementia: The Northern Manhattan Study 94%
- Profiles of cognitive change in preclinical Alzheimer's disease using change-point analysis 93%
Similar papers in this journal
- Little genomic support for cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers 95%
- A FinnGen pilot clinical recall study for Alzheimer’s disease 94%
- Manifestations of genetic risk for Alzheimer's Disease in the blood: a cross-sectional multi-omic analysis in healthy adults aged 18-90+ 94%
Similar papers in this journal
- Relationship of plasma biomarkers to digital cognitive tests in alzheimer's disease 96%
- Extensive memory testing improves prediction of progression to MCI in late middle age 95%
- Blood metabolites predicting Mild Cognitive Impairment in the Study of Latinos-Investigation of Neurocognitive Aging (HCHS/SOL) 95%
Similar papers in this journal
- Sex differences in the association of mild behavioral impairment with cognitive aging 96%
- Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals 95%
- Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers 95%